Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study

E. Rubinstein, S. K. Cammarata, T. H. Oliphant, R. G. Wunderink, J. Labrooy, J. L. Moran, B. Richards, D. Grimard, S. J. Landis, C. Rotstein, E. Chavez, R. Northland, V. Triantafilo, P. Vasquez, V. Kolek, M. Kucera, P. Reiterer, I. Weidenhoffer, C. Andrews, I. McLarenM. Street, T. Ali-Malkkilä, J. Heikkinen, P. Kairi, M. Valtonen, B. Georges, L. Holzapfel, A. Leon, C. D. Martin, P. Maurette, J. F. Muir, M. Ossart, B. Veber, J. Lukacs, G. Nagy, Z. Rott, R. Raz, K. Riesenberg, A. Yinnon, M. Molinari, G. Castro, G. Fabian, M. Gaca, L. Krawczyk, J. Malolepszy, R. Szulc, L. Wolowicka, A. G. Chuchalin, T. Fedorova, I. M. Kakhnovskii, V. G. Novozhenov, A. I. Sinopalnikov, J. G. Kilian, W. L. Michell, A. W. Sturm, J. Viljoen, R. Wood, J. M. Pueyo, M. Soler-Obradors, I. M. Baird, M. C. Birmingham, H. S. Bjerke, M. A. Brown, S. J.D. Chow, R. K. Daniels, T. Dickey, A. El-Solh, D. R. Graham, L. R. Grier, J. Hall, M. S. Harrison, M. T. Herbert, R. C. Hyzy, R. J. Kaner, L. S. Larsen, I. Leviton, S. C. Matchett, M. H. Metzler, M. L. Morganroth, A. R. Murthy, P. E. Nolan, N. H. Olson, L. B. Palmer, R. G. Postier, D. P. Remy, G. J. Richmond, M. H. Rosenthal, G. Sanchez, R. B. Schechter, S. J. Simon, T. W. Smith, B. Thompson, B. J. White, B. Hafkin, W. M. Todd, J. Timm, K. Hempsall, L. Schuemann

Research output: Contribution to journalArticle

422 Scopus citations

Abstract

Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.

Original languageEnglish (US)
Pages (from-to)402-412
Number of pages11
JournalClinical Infectious Diseases
Volume32
Issue number3
DOIs
StatePublished - 2001

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study'. Together they form a unique fingerprint.

  • Cite this

    Rubinstein, E., Cammarata, S. K., Oliphant, T. H., Wunderink, R. G., Labrooy, J., Moran, J. L., Richards, B., Grimard, D., Landis, S. J., Rotstein, C., Chavez, E., Northland, R., Triantafilo, V., Vasquez, P., Kolek, V., Kucera, M., Reiterer, P., Weidenhoffer, I., Andrews, C., ... Schuemann, L. (2001). Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clinical Infectious Diseases, 32(3), 402-412. https://doi.org/10.1086/318486